A new class of targeted therapy drugs called kinase inhibitors can now help treat some metastatic breast cancers. These drugs target two kinase proteins, called cyclin-dependent kinase 4 and 6, that normally regulate the cell cycle and division. There are three CDK 4/6 inhibitors available: palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio).
These drugs are primarily used in women with hormone receptor-positive and HER2-negative breast cancer. When they are combined with other hormone therapy, many women can have up to two years of their cancer not getting any worse. A common side effect was a decrease in white blood cells which can increase the risk of infection.
Read More